Less Invasive Surfactant Administration LISA
ProcedureLaryngoscopy with insertion of a small 16 gauge angiocatheter to administer FDA approved Surfactant, during spontaneous respirations.
NCT Number: NCT04209946
This study is being conducted to determine whether prophylactic administration of surfactant by the Less Invasive Surfactant Administration (LISA) method reduces the need for mechanical ventilation in the first 72 hours of life when compared to early Continuous Positive Airway Pressure (CPAP) alone.
Looking for future studies?
Notify Me24 week–29 week
All sexes
Interventional
Not applicable
University of California, Irvine, Irvine, California, United States
In order to allow for initial stabilization on CPAP, infants will be randomized by 1 hour of life. Consented infants that are assessed by a provider as clinically stable (i.e. HR> 100 bpm) and spontaneously breathing on CPAP will be randomized by computer generated randomization cards placed in opaque envelopes.
Randomization will be stratified by gestational age (24-26+6 weeks and 27-29+6 weeks) and labeled as such on each envelope. Multiples will be randomized to the same treatment group for ease of consent and family considerations.
Infants randomized to LISA will receive surfactant (Curosurf 2.5 mL/kg, based on estimated fetal weight) and must be given in the first 2 hours of life using a conventional or video laryngoscope and a small flexible 16 gauge angiocatheter.
All sites have agreed on using senior level physicians or practitioners that have prior experience with the LISA method. An orogastric tube will be placed into the stomach prior to laryngoscopy and the contents aspirated after the procedure to document any esophageal surfactant administration.
Infants randomized to early CPAP will be managed according to unit practice for preterm infants on CPAP.
Caffeine Administration:
If randomized to LISA, caffeine will be given prior to the LISA procedure. In contrast, if randomized to CPAP, caffeine will be given soon after birth. If infants in the CPAP group meet intubation criteria, and the loading dose of caffeine has not been administered, to avoid delay in intubation, caffeine will be given no later than thirty minutes after intubation.
As an unblinded trial it is critical that both groups are standardized to avoid bias towards one arm for intubation/treatment failure. Therefore, strict delivery room/NICU criteria will be used.
In the Delivery Room, criteria for intubation will be as specified in the Neonatal Resuscitation Program guidelines (7th Ed) and will include:
In the Neonatal Intensive Care Unit (NICU), randomized infants in both groups will only be intubated if they meet strict failure criteria :
Infants intubated prior to randomization will be excluded. Infants not consented prior to birth will also be excluded to avoid bias in patient selection.
For pragmatic purposes sites will be able to use their standard approach for non-invasive ventilation (NCPAP or NIMV).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Laryngoscopy with insertion of a small 16 gauge angiocatheter to administer FDA approved Surfactant, during spontaneous respirations.
Infant will remain on CPAP Therapy during spontaneous respirations
Time frame: Within 72 hours of life
Required intubation or meeting respiratory failure criteria of having a pCO2 greater than 65 mm Hg or an FiO2 greater than 0.4 for more than 2 hours in the first 72 hours of life
Time frame: Through study completion at discharge, up to 6 months of corrected gestational age
Number of days on mechanical ventilation and/or CPAP
Time frame: Up to 40 weeks of corrected gestational age
Requiring oxygen therapy greater than 0.21 at 36 weeks corrected age
Time frame: Through study completion at discharge, up to 6 months of corrected gestational age
Intraventricular hemorrhage (grades 3-4)
Time frame: Up to 2 years of corrected gestational age
Neurodevelopmental assessments using the Bayley Scales of Infant Development 4th ed. will be done at 2 years of corrected corrected age (22-26 months) for subjects who were randomized at birth to receive surfactant by the LISA method versus CPAP alone.
Time frame: 22-26 months corrected gestational age
Overall and Domain Scores- Ages and Stages, 3rd ed. Questionnaire
Time frame: Up to 40 weeks of corrected gestational age
Requiring more than one dose of surfactant
Time frame: Number of laryngoscopy attempts per Surfactant dose, up to 36 weeks of corrected gestational age
Total number of laryngoscopy attempts to administer surfactant via the LISA procedure
Time frame: Number of laryngoscopy attempts per Surfactant dose, up to 36 weeks of corrected gestational age
Total number of laryngoscopy attempts to administer surfactant via endotracheal intubation
Sharp HealthCare
Other
A Multicenter, Randomized Trial of Preterm Infants Receiving Caffeine and Less Invasive Surfactant Administration Compared to Caffeine and Early Continuous Positive Airway Pressure (CaLI Trial)
Acronym: CaLI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06609135
Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity
Worcester, Massachusetts, United States
View Trial DetailsNCT07049900
Bronchopulmonary Dysplasia, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Minneapolis, Minnesota, United States
View Trial DetailsNCT06224816
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Madrid, Spain
View Trial DetailsNCT06295484
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Toronto, Ontario, Canada
View Trial Details